Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati
BenzingaApr 17 09:13 ET
Express News | Mind Medicine (MindMed) Inc : Leerink Partners Initiates Coverage With Outperform Rating and $20 Price Target
Moomoo 24/7Apr 15 06:17 ET
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday. Shares of Roblox Corporation (NYSE:RBLX) rose during Wednesday's session following reports the company has rampe
BenzingaApr 10 10:56 ET
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday. Shares of Simulations Plus, Inc. (NASDAQ:SLP) rose sharply in today's pre-market trading aft
BenzingaApr 4 05:18 ET
Mind Medicine Inc. Statement Inaccessible
TipRanksApr 1 19:37 ET
Express News | MindMed Reports Voluntary Delisting From Cboe Canada; All Common Shares Will Remain Listed On Nasdaq
Moomoo 24/7Apr 1 17:28 ET
MindMed to Voluntarily Delist From CBOE Canada
Seeking AlphaApr 1 17:10 ET
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
BenzingaMar 29 12:43 ET
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
Welcome to a new episode of the Benzinga Psychedelics Podcast where we're joined by Robert Barrow, CEO of Mind Medicine (MindMed) (NASDAQ:MNMD), which has taken the development of LSD-based therapy to
BenzingaMar 27 10:25 ET
Mind Medicine (NASDAQ:MNMD) Is Leading the Surge in Psychedelic Therapies
TipRanksMar 27 04:49 ET
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
BenzingaMar 20 14:49 ET
The Next Great Biotech Boom Has Arrived
The U.S. Federal Drug Administration (FDA) has now designated psilocybin, a classical compound found in "magic mushrooms," as a "breakthrough...
PR NewswireMar 19 08:00 ET
Express News | HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $75 Price Target
Moomoo 24/7Mar 14 07:18 ET
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Clinical-stage psychedelics biopharma company Cybin Inc. (NYSE:CYBN) announced that the Food and Drug Administration has granted Breakthrough Therapy designation to CYB003, its proprietary deuterated
BenzingaMar 13 11:33 ET
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
Business WireMar 11 07:00 ET
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
Shortly following the news on FDA's "breakthrough therapy" designation and the 12-week clinical durability data on its LSD therapy for generalized anxiety, psychedelics biotech MindMed (NASDAQ:MNMD) a
BenzingaMar 8 13:01 ET
Numinus Wellness Congratulates MindMed on Positive Results From Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
VANCOUVER, BC, March 8, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care...
PR NewswireMar 8 07:00 ET
Mind Medicine Is Maintained at Outperform by RBC Capital
Mind Medicine Is Maintained at Outperform by RBC Capital
Dow JonesMar 8 05:46 ET
Express News | RBC Capital Maintains Outperform on Mind Medicine, Raises Price Target to $22
Moomoo 24/7Mar 8 05:36 ET
Psychedelics Stocks Fly as FDA Recognizes Mind Medicine's LSD Drug as Breakthrough Therapy
InvestingMar 7 15:24 ET
No Data
No Data